Bexson Biomedical

Actual: Nov 1, 2021

FDA pre-IND guidance received for BB106 preclinical/clinical programs; expanded indications to include major depression and suicidality

Why it matters: FDA pre-IND guidance is a positive regulatory interaction confirming the path forward. Expansion from pain to mental health indications broadens the commercial opportunity for subcutaneous ketamine delivery.

Actual: Jan 1, 2023

USPTO Patent #11,534,454 issued for SEVALENT formulation technology (proprietary subcutaneous ketamine formulation)

Why it matters: Patent protection for the drug-device combination. SEVALENT is a stabilized ketamine formulation designed for subcutaneous delivery via the AKESO wearable pump — bypassing IV administration and enabling home/field use.

Actual: Aug 1, 2023

AKESO wearable device field-tested with U.S. military at Northern Strike exercise for battlefield pain management; device co-developed with Stevanato Group

Why it matters: Military field testing validates the wearable drug-device in austere conditions. Battlefield pain is a high-value DoD use case. This was the last public update from Bexson — over 2.5 years of silence since.

Actual: Aug 15, 2023

No further public updates since August 2023; total raised ~$12.8M; no IND filing announced; website still active but no new content

Why it matters: Over 2.5 years of silence from a venture-backed biotech is a significant concern. The company had projected possible FDA approval by 2026 for post-op pain but has not disclosed IND filing or any clinical progress. Status is uncertain — may be quietly advancing in private development, facing fundraising difficulties, or winding down.